Jeffrey M Jacobson
Affiliation: Drexel University College of Medicine
- Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adultsJeffrey M Jacobson
Drexel University College of Medicine, Philadelphia, PA 19104, USA
J Infect Dis 198:1345-52. 2008..The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro...
- Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adultsJeffrey M Jacobson
Drexel University College of Medicine, Philadelphia, PA 19102, USA
Antimicrob Agents Chemother 53:450-7. 2009..In conclusion, ibalizumab administered either weekly or biweekly was safe and well tolerated and demonstrated antiviral activity. Further studies with ibalizumab in combination with standard antiretroviral treatments are warranted...
- Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19104, USA
J Infect Dis 201:1481-7. 2010..This study is the first to evaluate subcutaneous administration...
- Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 N 15th St, MS 461, Philadelphia, PA 19104, USA
Antimicrob Agents Chemother 54:4137-42. 2010..The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent...
- Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infectionChristopher J Bruno
Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
J Antimicrob Chemother 65:1839-41. 2010..Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1...
- Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trialBenigno Rodriguez
Division of Infectious Diseases and Center for AIDS Research, Case Western Reserve University University Hospitals of Cleveland, Cleveland, OH Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA University of Pittsburgh, Pittsburgh, PA Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD Department of Medicine, Rush University Medical Center, Chicago, IL ViroStatics srl, Sassari, Italy Genetic Immunity, Budapest, Hungary Genetic Immunity, McLean, VA and Social and Scientific Systems, Inc, Silver Spring, MD
J Acquir Immune Defic Syndr 64:351-9. 2013..DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses...
- Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trialNoah McKittrick
University of Pennsylvania, Philadelphia, PA 19104, USA
Ann Intern Med 158:19-26. 2013..HIV-infected persons have less robust antibody responses to influenza vaccines...
- Combinatorial approaches to the prevention and treatment of HIV-1 infectionVanessa Pirrone
Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, New College Building, Philadelphia PA 19102, USA
Antimicrob Agents Chemother 55:1831-42. 2011..The shift in focus within the microbicide development field from single compounds to combination approaches is also explored...
- Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integrationLivio Azzoni
1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
J Infect Dis 207:213-22. 2013..Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication...
- Effects of highly active antiretroviral therapy on HIV-1-associated oral complicationsZahida Parveen
Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Curr HIV Res 5:281-92. 2007..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented...
- Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infectionJoseph A Fraietta
Department of Microbiology and Immunology, Center for Immunology and Vaccine Science, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
PLoS Pathog 9:e1003658. 2013....
- Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virionsArangassery Rosemary Bastian
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, 245N 15th Street, New College Building, Room No, 11102, Philadelphia, PA 19102, USA
Retrovirology 10:153. 2013..We examined the underlying mechanism of action of the peptide triazole thiol, KR13 that has been shown previously to specifically bind gp120, block cell receptor site interactions and potently inhibit HIV-1 infectivity...
- A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral TherapyJeffrey M Jacobson
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA AIDS Clinical Trials Group, Statistical and Data Analysis Center, Harvard University School of Public Health, Boston, MA Vaccine and Gene Therapy Institute, Port Saint Lucie, FL Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI Department of Immunology Microbiology, Rush University School of Medicine, Chicago, IL Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Montreal, CA Division of Infectious Diseases, Department of Medicine, University of California, San Diego, School of Medicine, San Diego, CA Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN Social and Scienti x fb01 c Systems, Inc, Silver Springs, MD Frontier Sciences, Buffalo, NY and Division of AIDS, NIAID, Bethesda, MD
J Acquir Immune Defic Syndr 66:399-406. 2014..Palifermin (keratinocyte growth factor), by providing support to the thymic epithelium, promotes lymphopoiesis in animal models of bone marrow transplantation and graft-versus-host disease...
- Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapyBrandon Palermo
Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
HIV Clin Trials 12:222-7. 2011..To better characterize the relationship between body mass index (BMI) and CD4+ T-lymphocyte recovery in HIV disease...
- Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairmentLuna Li
Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, MS 1013A, Philadelphia, PA 19102, USA
J Neurovirol 17:92-109. 2011....
- Long-Acting HIV Therapy for Injection Drug UsersJeffrey M Jacobson; Fiscal Year: 2010..We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence. ..